Background: Although systemic therapy for metastatic breast cancer (MBC) continues to evolve, there are scant data to guide physicians and patients when symptoms develop. In this article, the authors report the frequency and durability of palliative procedures performed in the setting of MBC.
Methods: From July 2002 to June 2003, 91 patients with MBC underwent 109 palliative procedures (operative, n=76; IR n=39, endoscopic n=3). At study entry, patients had received a mean of 6 prior systemic therapies for metastatic disease. System-specific symptoms included neurologic (33%), thoracic (23%), musculoskeletal (22%) and GI (14%). The most common procedures were thoracostomy with or without pleurodesis (27%), craniotomy with resection (19%) and orthopedic open reduction/internal fixation (19%).
Results: Symptom improvement at 30 days and 100 days was reported by 91% and 81% of patients, respectively, and 70% reported continued benefit for duration of life. At a median interval of 75 days from intervention (range, 8-918 days), 23 patients (25%) underwent 61 additional procedures for recurrent symptoms. The durability of palliation varied with system-specific symptoms. Patients with neurologic or musculoskeletal symptoms were least likely to require additional maintenance procedures (P<.0002). The 30-day complication rate was 18% and there were no procedure-related deaths. At a median survival of 37.4 mos from MBC diagnosis (range, 1.6-164 months) and 8.4 months after intervention (range, 0.2-73 months), 7 of 91 patients remained alive.
Conclusions: Palliative interventions for symptoms of MBC are safe and provide symptom control for the duration of life in 70% of patients. Definitive surgical treatment of neurologic or musculoskeletal symptoms provided the most durable palliation; interventions for other symptoms frequently require subsequent procedures. The longer median survival for patients with MBC highlights the need to optimize symptom control to maintain quality of life.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465203 | PMC |
| http://dx.doi.org/10.1002/cncr.25034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Trajectories of Older Adults Served by an Emergency Department/Hospital-Based Elder Mistreatment Response Program.
J Am Geriatr Soc
January 2025
Department of Emergency Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, New York, New York, USA.
Background: An emergency department (ED) visit or hospitalization provides an opportunity to identify elder mistreatment and initiate intervention, but this seldom occurs. To address this, we developed the Vulnerable Elder Protection Team (VEPT), a novel interdisciplinary consultation service. We explored the long-term trajectories of patients receiving VEPT evaluation and intervention.
View Article and Find Full Text PDFImproving Advanced Care Planning Discussions at an Internal Medicine Clinic.
Cureus
December 2024
Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, USA.
Objective: The project aimed to standardize advanced care planning (ACP) at an internal medicine clinic by initiating physician-patient communication regarding the patient's knowledge, understanding, and openness to pursuing advanced medical directives.
Methods: Data collection was conducted from February 1 to April 1, 2024, with the study concluding on April 24, 2024. ACP was facilitated through an initial standardized six-question pre-intervention survey in both English and Spanish.
Abscopal Effect in a Patient With Metastatic Melanoma Receiving Hypofractionated Radiation Therapy and Dual Immune Checkpoint Inhibition: A Case Report.
Cureus
November 2024
Radiation Oncology, Fox Chase Cancer Center, Temple University Hospital, Philadelphia, USA.
Concurrent with the increasing utilization of immune checkpoint inhibitors (ICIs) in melanoma, there has been renewed interest in understanding the potential interplay between radiation therapy (RT) and the immune system. One such phenomenon is the abscopal effect, where localized treatments, such as RT, not only shrink the targeted tumor but also induce shrinkage of untreated tumors elsewhere in the body. Here, we report a case of an abscopal effect in a 63-year-old patient with metastatic melanoma who was progressing on first-line dual ICI therapy but experienced a rapid and durable systemic response following the administration of hypofractionated palliative RT to a large primary melanoma skin tumor.
View Article and Find Full Text PDFSafety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study.
Blood Adv
December 2024
Charité, University Medical Center Berlin, Campus Benjamin Franklin, Berlin, Germany.
Article Synopsis
- Glofitamab, a bispecific antibody targeting CD20 and CD3, shows promise for treating relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) in heavily pretreated patients, with an overall response rate of 47%.
- In a study involving 70 patients in Germany, Austria, and Switzerland, the median number of prior treatments was four, with notable safety concerns including cytokine release syndrome in 40% of cases.
- Important findings indicate that elevated LDH levels predict poorer outcomes, and recent treatment with bendamustine may reduce the efficacy of glofitamab, suggesting careful treatment sequencing is essential.
Intraductal ablation therapy for malignant biliary obstruction.
Langenbecks Arch Surg
December 2024
Department of Interventional Treatment, First Hospital of Qinhuangdao, No.258 Wenhua Road, Qinhuangdao, Hebei, 066099, China.
Background: Malignant biliary obstruction is usually attributed to the enlargement of tumors within or adjacent to the biliary tract, leading to blockage or compression of the bile ducts. Common causes include pancreatic head cancer, bile duct cancer, gallbladder cancer, liver cancer, and metastatic diseases. Most cases have an insidious onset, lack effective early screening methods, and 70% of patients cannot undergo surgical resection, with a 5-year survival rate of about 30%.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!